National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nusinersen (Spinraza®). HTA ID: 20044

Nusinersen (Spinraza®) is indicated for the treatment of 5q spinal muscular atrophy (SMA) in adults patients (>18 years).

 

NCPE Assessment Process Complete
Rapid review commissioned 28/09/2020
Rapid review completed 29/10/2020
Rapid Review outcome A full HTA is recommended to assess the clinical and cost-effectiveness compared to the current standard of care.